Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Posted by George Bondi on Sep 13th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $82,336,727.20. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00.
On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00.
On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71.

Halozyme Therapeutics Stock Up 0.2%

NASDAQ HALO opened at $107.20 on Friday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $111.15. The company has a 50 day moving average of $93.73 and a 200-day moving average of $76.97. The company has a market cap of $12.17 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Talon Private Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $839,000. Sequoia Financial Advisors LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $359,000. Tidal Investments LLC increased its position in Halozyme Therapeutics by 13.5% during the 2nd quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock worth $14,895,000 after purchasing an additional 22,707 shares in the last quarter. WINTON GROUP Ltd lifted its stake in Halozyme Therapeutics by 704.6% in the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after purchasing an additional 52,848 shares during the last quarter. Finally, Engineers Gate Manager LP lifted its stake in Halozyme Therapeutics by 6.7% in the 2nd quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company’s stock valued at $3,614,000 after purchasing an additional 2,889 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HALO. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $91.20.

Get Our Latest Stock Report on Halozyme Therapeutics

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.